58
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

          EXPEDITION and EXPEDITION2 were identically designed placebo-controlled phase 3 studies assessing effects of solanezumab, an antiamyloid monoclonal antibody binding soluble amyloid-β peptide, on cognitive and functional decline over 80 weeks in patients with mild-to-moderate Alzheimer's disease (AD). Primary findings for both studies have been published.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Alzheimer's disease: the amyloid hypothesis on trial.

            The pathogenesis of Alzheimer's disease is complex. The amyloid hypothesis has directed research efforts for many years, but it has recently been questioned after failed drug trials. Here, we review the evidence for and against and suggest that it might be premature to abandon the amyloid hypothesis.
              Bookmark

              Author and article information

              Journal
              New England Journal of Medicine
              N Engl J Med
              New England Journal of Medicine (NEJM/MMS)
              0028-4793
              1533-4406
              January 25 2018
              January 25 2018
              : 378
              : 4
              : 321-330
              Article
              10.1056/NEJMoa1705971
              29365294
              e2fd1a7d-aba4-4669-8501-b0b79d3f5006
              © 2018
              History

              Comments

              Comment on this article